Calmark extends the shelf life of the test cassettes to 2 years.
Calmark Sweden AB (publ) announces today that they have extended the shelf life of the test cassettes to 24 months. The decision has been taken after internally conducted studies. The batch that has now been produced can be used until January 2026, which is deemed to meet the market's needs.
Calmark has produced a new batch of test cassettes using its fully automated production line to meet upcoming deliveries. As a medical technology manufacturer, it has great demands on itself to prove the durability of its products. This can be difficult with new products and real-time studies are often required to prove the products' durability. Calmark now has data proving that the test cassettes have satisfactory function and performance after 24 months on the shelf.
"I am pleased that both the production line and the product are so stable that this became something of a formality. We have saved test cassettes so that we can extend the shelf life even further but judge that 24 month is sufficient for all our customers.” says Michael Lundh, CTO at Calmark.
“This is an important milestone for us. Having a 2-year shelf life on the product is important both for us and our distributors. It facilitates sales to end customers, planning and logistics.” says Anna Söderlund, CEO at Calmark.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags: